Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more
Bio-Thera Solutions Ltd (688177) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.66 Billion CNY
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) has total liabilities worth CN¥1.66 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bio-Thera Solutions Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bio-Thera Solutions Ltd Competitors by Total Liabilities
The table below lists competitors of Bio-Thera Solutions Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PC Jeweller Limited
NSE:PCJEWELLER
|
India | ₹16.77 Billion |
|
Real Brokerage Inc
NASDAQ:REAX
|
USA | $91.62 Million |
|
Stolt-Nielsen Limited
PINK:SOIEF
|
USA | $3.35 Billion |
|
Colony Bankcorp Inc.
NYSE:CBAN
|
USA | $3.36 Billion |
|
PolyPeptide Group AG
SW:PPGN
|
Switzerland | CHF442.08 Million |
|
Shandong Xinneng Taishan Power Generation Co Ltd
SHE:000720
|
China | CN¥2.75 Billion |
|
Universal Cement Corp
TW:1104
|
Taiwan | NT$5.62 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Bio-Thera Solutions Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio-Thera Solutions Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio-Thera Solutions Ltd (2016–2024)
The table below shows the annual total liabilities of Bio-Thera Solutions Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.50 Billion | +39.38% |
| 2023-12-31 | CN¥1.07 Billion | +87.67% |
| 2022-12-31 | CN¥572.48 Million | +7.96% |
| 2021-12-31 | CN¥530.27 Million | +36.82% |
| 2020-12-31 | CN¥387.56 Million | +1.01% |
| 2019-12-31 | CN¥383.68 Million | +74.85% |
| 2018-12-31 | CN¥219.44 Million | -19.14% |
| 2017-12-31 | CN¥271.39 Million | +56.10% |
| 2016-12-31 | CN¥173.86 Million | -- |